Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients

Overview

Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are characterized by the accumulation of fat in the liver. The diagnosis of these two entities is achieved by histology and neither imaging nor biochemical markers are accurate enough to discriminate them. At the contrary of HS, NASH features hepatocyte necrosis, inflammation and fibrosis of variable intensity that could progress and ultimately evolve to cirrhosis. Therefore, it is important to distinguish between HS and NASH in order to treat the patients accordingly. In this study, the investigators aim to understand the molecular mechanisms that govern the transition from benign steatosis to complicated NASH. The investigators will analyze by "Q-RT-PCR" and "DNA microarray" technologies in the liver of obese patients, the expression of genes that are susceptible to be involved in the pathogenesis of NAFLD and identify the potential signaling pathways responsible for the progression of the disease.

Full Title of Study: “Evaluation of Non Alcoholic Metabolic Liver Diseases in Patients Harboring Central Adiposity and Insulin Resistance by Biochemical and Functional Genomic Approaches”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 2011

Interventions

  • Procedure: Bariatric surgery
    • Gastric bypass.
  • Procedure: cholecystectomy or benign liver tumor removal
    • cholecystectomy or benign liver tumor removal

Arms, Groups and Cohorts

  • T
    • (n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
  • A
    • (n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
  • B
    • (n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).

Participating in This Clinical Trial

Inclusion Criteria

  • Group T(n=30): patient without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor – Group A (n=30): patient with central adiposity, insulin resistance and hepatic steatosis (histology). – Group B (n=30): patient with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology). Exclusion Criteria:

  • viral or autoimmune hepatitis – hematochromatosis – alcohol consumption (> 20 g/24h women, >30 g/24h men) – type 1 diabetes – inflammation or infection before procedure – abnormal hemostasis or coagulation- pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Strasbourg, France
  • Provider of Information About this Clinical Study
    • Christine GEILLER, Direction de la Recherche Clinique et de l’Innovation – Hôpitaux Universitaires de Strasbourg
  • Overall Official(s)
    • Michel DOFFOEL, MD, Principal Investigator, Hôpitaux Universitaires de Strasbourg
  • Overall Contact(s)
    • Ahmed Nassim DALI YOUCEF, PHD, (33) 3.69.55.11.84, ahmed.nassim.dali.youcef@chru-strasbourg.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.